CVSA vs PG
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
CVSA presents a dichotomy between strong operational performance and deteriorating technicals. While the Piotroski F-Score of 4/9 indicates stable but non-optimal financial health, the company boasts an exceptional earnings track record with consistent beats over 25 quarters. Valuation is attractive on a PEG basis (0.82), though the current price of $107.63 trades at a premium to both the Graham Number ($77.96) and Intrinsic Value ($95.4). The primary concerns are a bearish technical trend (-29.6% over 6 months) and weak liquidity ratios.
PG exhibits a stable financial foundation with a Piotroski F-Score of 6/9, but it is severely overvalued relative to its deterministic baselines. The current price of $145.71 represents a massive premium over the Graham Number ($58.45) and Intrinsic Value ($47.25), while a PEG ratio of 3.92 indicates the valuation is disconnected from its stagnant growth. Negative earnings growth (-5.40% YoY) combined with bearish insider activity and a 0/100 technical trend suggests significant downside risk despite the company's operational efficiency.
Compare Another Pair
Related Comparisons
CVSA vs PG: Head-to-Head Comparison
This page compares Covista Inc. (CVSA) and The Procter & Gamble Company (PG) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.